SPECIAL EVENT: “Geraldo Rivera Show” to Feature AxoGen, Inc. CEO Karen Zaderej to Discuss Role of Nerve Repair in Preserving Erectile Function After Prostatectomy – Final in a Series of Three Interviews
Interview Airs June 18, 2015, Host Geraldo Rivera,10:52 AM ET | 9:52 AM CT | 7:52 AM PT
ALACHUA, FL, June 18, 2015 – AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Executive Officer Karen Zaderej will be interviewed in a special three-day Q&A miniseries on the “Geraldo Rivera Show,” hosted by Geraldo Rivera and broadcast on 77 WABC from New York City. In this finale to a three-part interview, Ms. Zaderej will discuss the promising ability of nerve repair to preserve erectile function after nerve-sparing radical prostatectomy and the work done to date in this area. High rates of impotence and incontinence following radical prostatectomy make this a topic of interest for all.
All shareholders, analysts, industry professionals, health care providers and anyone experiencing symptoms of a nerve injury are encouraged to listen to the broadcast to learn more about options in nerve repair. Broadcast details for the third of the three segments are as follows:
About Geraldo Rivera
Geraldo Rivera: A three-time recipient of the 2000 Robert F. Kennedy journalism award. He has received more than 170 awards for journalism, including the prestigious George Foster Peabody Award, three national and seven local Emmys, two Columbia-Dupont and two additional Scripps Howard Journalism Awards. Rivera is a graduate of the University of Arizona and Brooklyn Law School and is the author of seven books. www.geraldo.com/ | http://www.wabcradio.com/geraldorivera/
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
To learn more about AxoGen and to sign up for news alerts, visit www.AxoGenInc.com.
Cautionary Statement Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Released June 18, 2015